ImmunityBio (IBRX) Non-Current Debt (2015 - 2026)

ImmunityBio (IBRX) has 8 years of Non-Current Debt data on file, last reported at $404.3 million in Q1 2026.

• On a quarterly basis, Non-Current Debt rose 36.46% year-over-year to $404.3 million in Q1 2026; TTM through Mar 2026 was $404.3 million, a 36.46% increase from a year earlier, with the FY2025 full-year figure at $324.6 million, up 14.14% from the prior year.
• Non-Current Debt for Q1 2026 stood at $404.3 million, up from $324.6 million in the prior quarter.
• Over the last five years, Non-Current Debt for IBRX reached as high as $480.0 million in Q3 2023 and fell as low as $108.8 million in Q2 2024.
• Historically, Non-Current Debt has averaged $279.5 million across 5 years, with a median of $307.0 million in 2025.
• Across the five-year window, Non-Current Debt plunged 76.85% in 2024 and soared 184.45% in 2025, its largest moves.
• Year by year, Non-Current Debt stood at $373.3 million in 2022, then sank by 58.37% to $155.4 million in 2023, then surged by 83.0% to $284.4 million in 2024, then advanced by 14.14% to $324.6 million in 2025, then grew by 24.55% to $404.3 million in 2026.
• Per Business Quant data, the three most recent Non-Current Debt figures were $404.3 million in Q1 2026, $324.6 million in Q4 2025, and $316.1 million in Q3 2025.